Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

- PMLiVE

FDA briefing document backs J&J’s one-dose COVID-19 vaccine

Company is seeking an emergency use authorisation in the US

- PMLiVE

Moderna announces plans for COVID-19 variant-specific booster jabs and new production targets

Company is developing variant-specific COVID-19 vaccine candidate

- PMLiVE

Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds

Study included around 1.2 million people in Israel

- PMLiVE

Communiqué Awards 2021 entry deadline is two weeks away!

The deadline is 11 March – make sure you start working on your entries now

- PMLiVE

FDA updates guidance for COVID-19 vaccine makers addressing new variants

FDA said that it expects manufacturing information for modified vaccines to remain generally the same

- PMLiVE

Integrating competitive intelligence into business development, licensing and M&A strategy

The advantages of partnering with a competitive intelligence or knowledge management team

What One Thing

Why we need to look at rare diseases in a different way

28 February 2021, Rare Disease Day aims to raise awareness of rare diseases and the impact they have on patients’ lives.

Bedrock Healthcare Communications

- PMLiVE

Why we need to look at rare diseases in a different way

28 February 2021, Rare Disease Day aims to raise awareness of rare diseases and the impact they have on patients’ lives.

Origins – The Patient Focused Specialists

The Good Ideas Group – Showreel

The Good Ideas Group

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin

Company announced clinical hold on gene therapy earlier this month after suspected serious adverse reaction

- PMLiVE

Reaching patients and HCPs during the pandemic

COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links